Literature DB >> 8052939

[Radiation pneumonitis and pulmonary fibrosis after the CT-planned radiotherapy of bronchial carcinoma].

G Müller1, I C Kiricuta, J Stiess, W Bohndorf.   

Abstract

PURPOSE: Examination of the influence of total tumor dose, additional therapy and age on the development of radiation pneumonitis and lung fibrosis. PATIENTS AND METHODS: Two hundred and sixteen patients with squamous cell carcinoma of the lung were examined retrospectively. Hundred and eighty-three of them received a percutaneous radiation therapy of the primary tumor and the mediastinal and ipsilateral hilar lymph nodes. The majority of 130 patients was given radiotherapy as only treatment, 27 were irradiated after resection and 26 received chemo- and radiotherapy. Treatment volume was determined by three-dimensional planning using chest CT-scan. The irradiation was administered in a first series of 56 Gy and a following boost to the primary and involved lymph nodes to a total dose of 70 Gy. There was one daily irradiation with 2 Gy 5 days a week. Post-resectional radiation encompassed the bronchus stump and the mediastinum with a total dose of about 60 Gy.
RESULTS: Sixty-eight of the 183 irradiated patients developed a pneumonitis (37.2%) and 60 a lung fibrosis (32.8%). The most important factor was the administered total irradiation dose (p < 0.001). There was no pneumonitis documented below 36 Gy and no fibrosis below 40 Gy. An additional chemotherapy did not increase the incidence (pneumonitis after radiotherapy 35.4%, after radio- and chemotherapy 34.6%; fibrosis after radiotherapy 33.9%, after radio- and chemotherapy 38.5%). Particularly high was the incidence of pneumonitis when radiotherapy followed resection (48.2%) while the rate of fibrosis in this group of patients was relatively low (22.2%). Age of patients did not affect the frequency of pneumonitis while fibrosis significantly occurred more often with increasing age (p = 0.037).
CONCLUSION: The total dose affecting the normal lung tissue is the most important factor for the development of radiation pneumonitis and lung fibrosis. It is recommended to keep the treatment volume appropriate to the individual extend of tumor. Good results are achieved with a computer supported CT-planning which helps to gain minimal burdening of normal tissue.

Entities:  

Mesh:

Year:  1994        PMID: 8052939

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  5 in total

1.  [The inhalation versus systemic prevention of pneumonitis during thoracic irradiation].

Authors:  J Pagel; M Mohorn; K H Kloetzer; M Fleck; T G Wendt
Journal:  Strahlenther Onkol       Date:  1998-01       Impact factor: 3.621

Review 2.  A literature-based meta-analysis of clinical risk factors for development of radiation induced pneumonitis.

Authors:  Ivan R Vogelius; Søren M Bentzen
Journal:  Acta Oncol       Date:  2012-09-05       Impact factor: 4.089

3.  NORMAL TISSUE REACTIONS TO CHRONIC RADIATION EXPOSURE IN MAN.

Authors:  A V Akleyev
Journal:  Radiat Prot Dosimetry       Date:  2016-07-29       Impact factor: 0.972

4.  A new method to deliver supraclavicular radiation in breast radiotherapy for lung sparing.

Authors:  Bo Yang; Zhang Dong; Mu-Han Lin; C-M Ma
Journal:  J Appl Clin Med Phys       Date:  2011-04-18       Impact factor: 2.102

5.  Inhalative steroids as an individual treatment in symptomatic lung cancer patients with radiation pneumonitis grade II after radiotherapy - a single-centre experience.

Authors:  C Henkenberens; S Janssen; M Lavae-Mokhtari; K Leni; A Meyer; H Christiansen; M Bremer; N Dickgreber
Journal:  Radiat Oncol       Date:  2016-02-02       Impact factor: 3.481

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.